Valvular & structural heart disease

Long-Term Follow-Up in Severe Mitral Stenosis With Low Transmitral Diastolic Pressure Gradient: From MASTER Registry

Circ Cardiovasc ImagingPublished registry

Authors' conclusion

Patients with severe MS and low MDPG carried a greater risk of adverse events than those with high MDPG and had less frequent and delayed mitral valve intervention. Also, it is not necessarily indicative of milder hemodynamic encumbrance. Left atrial reservoir strain could help identify a subgroup associated with poor prognosis in patients with low MDPG.

Study context

Population
Patients with severe rheumatic mitral stenosis (MS) (mitral valve area ≤1.5 cm 2 )patients with severe MS
Participants
1,248 patients
Exposure
Low vs high mean diastolic pressure gradient (MDPG)
  • Low MDPGn = 322
  • High MDPGn = 926reference
Outcome
composite of:
  • All-cause mortality
  • Stroke
Follow-up
Mean 6.8±5.9 years
Methodological detailsMulticenter, long-term
  • Multicenter
  • Long-term

Main finding

As reported in the abstract

low MDPG vs high MDPGHazard ratio (95% CI)P value
More events with low MDPG
1.56(1.15–2.12)
P = 0.004
Multivariable model
1.42(1.02–1.97)
P = 0.038
Patients experienced major adverse events
194 (15.5%)

Observational data: associations, not effects.

Further findings

Baseline characteristics

Mean age
59±13 years
Men
25%
Atrial fibrillation
74%
Patients with low MDPG were older and had a higher prevalence of atrial fibrillation

Poor outcome with decreased left atrial reservoir strain (subgroup of patients with low MDPG)

Decreased left atrial reservoir strain, hazard ratio (95% CI, 1.25-8.31; P =0.016)
3.22
  • Independently associated

Original publication

Long-Term Follow-Up in Severe Mitral Stenosis With Low Transmitral Diastolic Pressure Gradient: From MASTER Registry. Circ Cardiovasc Imaging. Published 16 July 2025. doi:10.1161/circimaging.125.018124

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.